The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / NSAIDs: The Heart of the Controversy

NSAIDs: The Heart of the Controversy

June 1, 2007 • By Kurt Ullman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Nonsteroidal anti-inflammatory drugs (NSAIDs) have received much negative attention during the last few years—particularly because of concerns about cardiovascular side effects when they are used to treat RA and osteoarthritis. These concerns contributed to Merck’s decision to withdraw the COX-2 inhibitor rofecoxib from the market in 2004, followed a year later by Pfizer’s withdrawal of a similar medication, valdecoxib. The controversy again heated up early in 2007 when the American Heart Association (AHA) issued a Scientific Statement containing guidelines for the use of all NSAIDs in those with cardiovascular problems or risk factors for ischemic heart disease.1

You Might Also Like
  • Diclofenac Patch, Piroxicam Most Effective Topical NSAIDs for Osteoarthritis
  • FDA Issues Stronger Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Warning
  • Are NSAIDS Even Less Safe Than We Thought?
Explore This Issue
June 2007
Also By This Author
  • Medical Societies Ask, What’s in a Name?

What the AHA Statement Says

“Our Scientific Statement was a review of the evidence suggesting that NSAIDs may impose an increased risk of heart attack, stroke, and death in patients with known heart disease or who are at risk for ischemic heart disease,” says Elliott M. Antman, MD, director of the coronary care unit at Brigham and Women’s Hospital in Boston and lead author of the article. “Although disease-modifying therapy is very much in the front line of treatment to decrease inflammation and joint damage, at some point consideration will be given to relieving pain. The statement indicates the level of risk as perceived by the American Heart Association for the various drugs and recommends a five-step approach starting with those medications seen as having less cardiovascular risk and moving progressively toward those with higher cardiovascular risks.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Steven B. Abramson, MD
The rheumatologist knows that all NSAIDs can cause many kinds of side effects and they must be used at the lowest possible dose for the shortest possible amount of time.
—Steven B. Abramson, MD

While stressing that they are not trying to overstep the domain of rheumatologists, the authors suggest what they called a “stepped care approach” starting off with acetaminophen, acetylsalicylic acid (ASA), and narcotic analgesics; followed by nonacetylated salicylates; then non COX-2 selective medications; NSAIDs with some COX-2 activity; and reserving COX-2 selective drugs for a last resort. (See Figure 1)

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

click for large version
figure 1: The AHA guidelines for NSAID use recommend this stepped approach to pharmacological therapy for all patients with known cardiovascular disease or who are at risk for ischemic heart disease. Source: Circulation. 2007;115:1639

“[The COX-2 inhibitors] are a class of drugs that are not necessarily more effective than traditional drugs, are associated with an increased cardiovascular risk, and do not offer as much gastrointestinal tract protection as originally thought,” says Dr. Antman. “Given all of that, the Scientific Statement says that in patients with heart disease or risk for ischemic heart disease, they should be the last group of medications tried.”

Rheumatologists Take a Different View

There was a consensus among the rheumatologists interviewed for this article that the AHA Statement was oversimplified and only addressed the cardiovascular side effects while ignoring concerns about other types of adverse effects.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Analgesics, Drug Updates, Safety Tagged With: AC&R, dosage, Nonsteroidal anti-inflammatory drugs (NSAIDs), patient care, rheumatologist, Safety, side effectIssue: June 2007

You Might Also Like:
  • Diclofenac Patch, Piroxicam Most Effective Topical NSAIDs for Osteoarthritis
  • FDA Issues Stronger Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Warning
  • Are NSAIDS Even Less Safe Than We Thought?
  • Study Examines Why Patients Exceed Recommended Doses of Ibuprofen & NSAIDs

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.